TDO2 and cancer: However, in cancer types in which SLC7A5 is co-expressed with TDO and not with IDO (colon and rectum adenocarcinomas, lung adenocarcinoma and lung squamous cell carcinoma) [73], AhR activation is likely to involve only TDO activity.